CD8A and ovarian carcinoma: As reported by Eggold et al., UHDR-RT could increase intratumoral CD8+ T-cell infiltration in combination with PD-1 blockade therapy in an ovarian cancer model in both anti-PD-1 antibody-resistant and anti-PD-1 antibody-sensitive settings.29 Similarly, PD-1 monoclonal antibodies combined with UHDR-RT significantly reduced the tumor volume in the MOC1_R mouse model.